Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE 6 Vulnerable
2022-502425-18-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in prostate adenocarcinoma comparing ADT + darolutamide with ADT + placebo (2 arms). Primary endpoint: Radiographic progression-free survival. Planned start Apr 2022; status: authorised.
02
Drugs
darolutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on 2022-502425-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502425-18-00.